Novo Nordisk is making yet another bet on obesity ... Septerna’s binding site has 80% to 90% sequence similarity across the three receptors, versus 40% to 60% for rival assets.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

created by Danish pharmaceutical company Novo Nordisk. The drug soared in popularity by offering a quicker fix to obesity, which is a growing health concern around the globe. Some people also take ...

In recent years, GLP-1 receptor agonists, such as Novo Nordisk's Wegovy and Eli ... guidance to stop pharmacists distributing Rybelsus (Semaglutide) to new patients, due to supply issues.

Once the world’s most widely used dieting program, Weight Watchers’ parent company, WW International, recently entered ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn ...

Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. ...

Novo Nordisk abstracts to be presented, some of these data for semaglutide are investigational: Predicting weight loss using self-reported, digitally collected, real-world data after initiation of ...